Neumora Therapeutics (NMRA) Common Equity (2022 - 2026)

Neumora Therapeutics' Common Equity history runs 5 years deep, the most recent figure standing at $70.7 million for Q1 2026.

• In Q1 2026, Common Equity fell 69.05% year-over-year to $70.7 million; the TTM figure through Mar 2026 stood at $70.7 million (down 69.05% YoY), while the FY2025 annual figure was $103.9 million, down 63.82% from the prior year.
• Common Equity for Q1 2026 stood at $70.7 million, down from $103.9 million in the prior quarter.
• The five-year high for Common Equity was $512.7 million in Q3 2023, with the low at -$513.5 million in Q2 2023.
• The 5-year median for Common Equity is $182.9 million (2025), against an average of $83.5 million.
• The sharpest annual moves came in 2023 and 2026: Common Equity jumped 221.49% in 2023, then plunged 69.05% in 2026.
• Neumora Therapeutics' Common Equity stood at -$446.8 million in 2022, then jumped by 204.97% to $469.1 million in 2023, then slumped by 38.8% to $287.1 million in 2024, then sank by 63.82% to $103.9 million in 2025, then slumped by 31.95% to $70.7 million in 2026.
• Business Quant data shows NMRA's Common Equity at $70.7 million in Q1 2026, $103.9 million in Q4 2025, and $132.2 million in Q3 2025.